- Home
- IBRX vs HUBG Comparison
IBRX vs HUBG Comparison
Compare IBRX & HUBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- HUBG
- Stock Information
- Founded
- IBRX 2014
- HUBG 1971
- Country
- IBRX United States
- HUBG United States
- Employees
- IBRX N/A
- HUBG N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- HUBG Oil Refining/Marketing
- Sector
- IBRX Health Care
- HUBG Consumer Discretionary
- Exchange
- IBRX Nasdaq
- HUBG Nasdaq
- Market Cap
- IBRX 2.4B
- HUBG 2.0B
- IPO Year
- IBRX N/A
- HUBG 1996
- Fundamental
- Price
- IBRX $2.06
- HUBG $33.31
- Analyst Decision
- IBRX Strong Buy
- HUBG Buy
- Analyst Count
- IBRX 5
- HUBG 8
- Target Price
- IBRX $11.35
- HUBG $47.13
- AVG Volume (30 Days)
- IBRX 8.8M
- HUBG 618.9K
- Earning Date
- IBRX 05-16-2025
- HUBG 05-08-2025
- Dividend Yield
- IBRX N/A
- HUBG 1.51%
- EPS Growth
- IBRX N/A
- HUBG N/A
- EPS
- IBRX N/A
- HUBG 1.70
- Revenue
- IBRX $14,745,000.00
- HUBG $3,946,390,000.00
- Revenue This Year
- IBRX $579.28
- HUBG $4.73
- Revenue Next Year
- IBRX $179.96
- HUBG $7.07
- P/E Ratio
- IBRX N/A
- HUBG $19.49
- Revenue Growth
- IBRX 2270.58
- HUBG N/A
- 52 Week Low
- IBRX $1.83
- HUBG $30.75
- 52 Week High
- IBRX $9.16
- HUBG $53.21
- Technical
- Relative Strength Index (RSI)
- IBRX 36.89
- HUBG 50.19
- Support Level
- IBRX $1.83
- HUBG $30.75
- Resistance Level
- IBRX $2.17
- HUBG $33.30
- Average True Range (ATR)
- IBRX 0.18
- HUBG 1.17
- MACD
- IBRX -0.05
- HUBG 0.33
- Stochastic Oscillator
- IBRX 23.56
- HUBG 75.71
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About HUBG Hub Group Inc.
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset light truck brokerage operations, along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub is somewhat acquisitive in that it often makes tuck-in acquisitions which expand its brokerage, last-mile, and dedicated offerings.